Microglia depletion fails to abrogate inflammation-induced sickness in mice and rats

Elisabeth G. Vichaya

Baylor College of Medicine

Sajida Malik

"RMIT University"

Luba Sominsky

"RMIT University"

Bianca G. Ford

University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences

Sarah J. Spencer

"RMIT University"

Robert Dantzer (✉ rdantzer@mdanderson.org)

University of Texas MD Anderson Cancer Center <https://orcid.org/0000-0001-9399-6107>

Research

Keywords: Lipopolysaccharide, Inflammation, Microglia, CSF-1 receptor antagonism, PLX5622, Running wheel activity, Fatigue, Anergia, Mouse

Posted Date: March 17th, 2020

DOI: <https://doi.org/10.21203/rs.2.18550/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Journal of Neuroinflammation on May 31st, 2020. See the published version at <https://doi.org/10.1186/s12974-020-01832-2>.

Abstract

Background: Production of inflammatory mediators by reactive microglial cells in the brain is generally considered the primary mechanism underlying the development of symptoms of sickness in response to systemic inflammation.

Methods: Depletion of microglia was achieved in C57BL/6 mice by chronic oral administration of PLX5622, a specific antagonist of colony stimulating factor-1 receptor, and in rats by a knock-in model in which the diphtheria toxin receptor was expressed under the control of the endogenous fractalkine receptor (Cx3cr1) promoter sequence. After successful microglia depletion, mice and rats were injected with a sickness-inducing dose of lipopolysaccharide according to a 2 (depletion versus control) x 2 (LPS versus saline) factorial design. Sickness was measured by body weight loss and decreased locomotor activity in rats and mice, and reduced voluntary wheel running in mice.

Results: Chronic administration of PLX5622 in mice and administration of diphtheria toxin to knock-in rats depleted microglia and peripheral tissue macrophages. However, it did not abrogate the inducible expression of proinflammatory cytokines in the brain in response to LPS and even exacerbated it for some of the cytokines. In accordance with these neuroimmune effects, LPS-induced sickness was not abrogated, rather it was exacerbated when measured by running wheel activity in mice.

Conclusions: These findings reveal that the sickness-inducing effects of acute inflammation can develop independently of microglia activation.

Introduction

Inflammation induces symptoms of sickness that are characterized by malaise, decreased appetite, fatigue, reduced sociability, increased slow wave sleep and fever(1). Experimental studies in rodent models of inflammation confirm that activation of the innate immune system induces behavioral alterations that are reminiscent of sickness and include decreases in locomotor activity, propensity to exercise and motivation in effort tasks(2). The mechanisms for these effects involve propagation of inflammation from the periphery to the brain via multiple pathways including afferent nerves, circulating immune mediators interacting with endothelial cells and macrophages in parts of the brain devoid of a fully functional blood-brain barrier, active transport of immune-derived molecules via the blood-brain barrier and, in some cases, trafficking of peripheral immune cells into the brain(3-6). This results in the activation of brain microglia and the local production of inflammatory cytokines which, by acting directly or indirectly on neurons, modify brain functions.

The key role of brain microglia in the development of inflammation-induced behavioral alterations has been demonstrated by various approaches mainly aiming at counteracting the production and action of inflammatory cytokines(7) or at normalizing microglial proinflammatory activity and phagocytosis using minocycline(8, 9). Recently, more targeted approaches have been proposed to eliminate microglia using genetic or pharmacological tools(10). Based on the observation that the development and survival of

microglia critically depends on colony stimulating factor-1 receptor (CSF-1R) signaling(11), CSF-1R antagonists have been successfully developed and are now commonly used to eliminate microglia. Continuous administration of these molecules to mice via their food results in a gradual depletion of Iba-1 and CD68 positive microglia in the brain within a few days of treatment, which persists until cessation of treatment and is then followed by repopulation(10). As CSF-1R antagonists can have off-target effects, it is useful to compare their effects to those achieved by genetic manipulation of microglia. There are several ways of genetically depleting microglia from knocking out genes that are essential for the survival and development of microglia to administration of immunotoxins such as diphtheria toxin to target the diphtheria toxin receptor genetically inserted in myeloid cells that express the fractalkine receptor CX3CR1(12). The objective of the present study was to determine whether ablation of microglia is sufficient to abrogate the behavioral signs of sickness induced by systemic administration of lipopolysaccharide (LPS) to mice and rats. For this purpose, we used the brain penetrant CSF-1R antagonist PLX-5622(13, 14) in mice and a knock-in rat model in which a diphtheria receptor is expressed under the control of the endogenous *Cx3cr1* promoter sequence(15, 16). Despite successful depletion of microglia in both models, mice and rats still responded to LPS by behavioral signs of sickness that were concomitant of a neuroinflammatory response.

Animals And Methods

Animals

Male C57BL/6J mice (Jackson Labs) were maintained in the MD Anderson animal male facility at 24°C and 50% humidity. They were provided a control or PLX5622 diet starting at 10 weeks of age. *Cx3cr1-Dtr* rats developed on a Wistar background(15, 16) were maintained at RMIT University at 22°C and 40-60% humidity. They were started in experiments between 9-12 weeks of age. All animals were housed on a 12-h light:dark cycle with food and water available *ad libitum*. All experiments were conducted with approval from their respective animal ethics committee. Rat experiments were conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, with approval from the RMIT University Animal Ethics Committee. Mice experiments were conducted in accordance with the NIH guidelines for care and use of laboratory animals, with approval from the MD Anderson Cancer Center Institutional Animal Care and Use Committee.

Depletion of microglia and LPS treatment

For the mice experiments, PLX5622 was provided by Plexxikon Inc. (Berkeley, CA). It was formulated in standard AIN-76A rodent chow at a concentration of 1,200 mg/kg (Research Diets, New Brunswick, NJ) and provided *ad libitum*. Control mice were given standard AIN-76A rodent chow. LPS (serotype O127:B8; Sigma-Aldrich, St-Louis, MO) was prepared in a solution of phosphate-buffered saline (PBS) at a concentration of 50 mg/ml and injected intraperitoneally at the dose of 0.5 mg/kg. Control mice received an equivalent volume of PBS.

The knock-in rat model used for depletion of CX3CR1 expressing myeloid cells has already been described in detail(15, 16). *Cx3cr1-Dtr* rats were injected subcutaneously twice with 25 ng/g diphtheria toxin. The injections were separated by an 8-h interval. LPS was injected at the dose of 0.1 mg/kg/ml at 48 h after the first injection of diphtheria toxin, which corresponds to the peak of microglia depletion(15, 16).

Behavioral testing

Mice were single housed with wireless low-profile running wheels (Med Associates, Fairfax, VT) to measure voluntary wheel running activity, which was quantified as total number of rotations per night (day running is not reported as mice display minimal activity during the day). Running wheels were provided to mice for 10-12 days prior to the initial LPS or PBS treatment to allow the mice to develop stable baseline running behavior. Locomotor activity in a new environment was measured for 5 min after mice were individually placed in an empty rectangular arena (18.4 x 29.2 cm). Activity was recorded by video camera and distance traveled was quantified using Noldus Ethovision XT Software (Noldus Information Technology, Leesberg, VA).

Open-field behavioral testing of rats was performed 2 and 24 h after LPS administration. Each rat was placed into an open-field box of 65 x 65 x 65 cm and filmed for 7 min. The video was analyzed using Ethovision. The arena was divided into two zones: a central zone and an edge zone. The frequency of center entries was assessed as a measure of anxiety and the distance covered per minute and total distance covered were assessed as measures of locomotor activity. The arena was thoroughly cleaned 70% ethanol between trials and animals.

Experimental design

The mouse experiment was organized according to a 2 (PLX5622 diet vs. control diet) x 2 (LPS vs. PBS) factorial design with 6 mice per group. The PLX5622 diet or the control diet was administered during the entire duration of the experiment. Mice were group housed with their assigned experimental diet for 12 days before they were single housed and provided with running wheels for the rest of the experiment. LPS or PBS was administered 1 month after the start of experimental diets. Locomotor activity in a new environment was measured 3 h after LPS or PBS treatment and voluntary wheel running was assessed continuously for 5 days after treatment. One week later, mice were submitted to a cross-over treatment so that mice that had initially received PBS were given LPS and vice versa. They were euthanized for tissue collection 6 h later to assess the effects of PLX5622 on the inflammatory response to LPS.

The rat experiment was organized according to a 2 (*Cx3cr1-Dtr* transgenic rats or wild type (WT) rats) x 2 (LPS vs. saline) factorial design with 8 rats per group. Rats were given LPS 48 h after diphtheria toxin. Locomotor activity was assessed 2 and 24 h post-LPS. Rats were euthanized for tissue collection immediately following the second locomotor activity assessment.

Tissue processing

Mice were euthanized by exposure to CO₂. Livers and brains were collected after intracardiac perfusion with PBS, snap frozen in liquid nitrogen, and stored at – 80°C until analyzed. RNA was extracted using E.Z.N.A. Total RNA Isolation kit (Omega Bio-Tek, Norcross, GA). RNA was reverse transcribed using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA) and analyzed by real-time PCR in the CFX384 Instrument (BioRad) using TaqMan Gene Expression Assays (Applied Biosystems). *Gapdh* was used as a house keeping gene. Primers are listed in Table 1.

Rats were deeply anesthetized with 150 mg/kg sodium pentobarbitone administered intraperitoneally. Livers and brains were collected. The hypothalamus was dissected from the left hemisphere of the brain over ice. Tissue samples were snap frozen in liquid nitrogen and stored at -80°C until analyzed. RNA was extracted from the liver and hypothalamus using QIAzol reagents and RNeasy Mini Kits (Qiagen, Valencia, CA, USA). RNA was reverse transcribed to cDNA using the QuantiTect Reverse Transcription kits (Qiagen) and analyzed by qRT-PCR in the Quantstudio 7 Flex instrument (Applied Biosystems) using Taqman Gene Expression Assays (Applied Biosystems, Mulgrave, VIC, Australia). *b-Actin* and *Gapdh* were used as housekeeping genes for liver and hypothalamus, respectively. Primers are listed in Table 2.

Data Analysis

Data were analyzed by appropriate two-way (PLX versus LPS or genotype x LPS) or one-way analyses of variance after exclusion of statistical outliers defined by Grubb's test for rat experiments. *Post hoc* comparisons of means were performed using Tukey tests or Bonferroni corrections for multiplicity. Data are presented as mean +/- standard error of the mean. Statistical significance was defined as p<0.05.

Results

1. Depletion of microglia by PLX5622 does not attenuate LPS-induced neuroinflammation and sickness behavior

1.1 PLX5622 eliminates microglia in the mouse brain but does not attenuate the brain inflammatory response to LPS

The extent of microglia depletion in mouse brain was quantified by the expression of *Cx3cr1* and *Itgam* mRNA. In accordance with previous reports, PLX5622 abrogated the expression of these microglial markers in the brain (PLX effect p<0.001, Fig. 1A, Table 3). Peripheral macrophages were also depleted by PLX5622 in the liver, as measured by the expression of *Csf1-R* (PLX effect p<0.001, Fig. 1B, Table 3).

As expected, LPS significantly increased the expression of *Il-1b*, *Tnf*, *Il-6* and the type I interferon responsive gene *Oas1a* in the brain and liver (LPS effect p<0.05-0.001, Fig. 1C & D). LPS also increased the gene expression of *Il-10* in the brain and liver although it was significant only in the brain (p<0.001). PLX5622 did not alter the brain inflammatory response to LPS with the exception of *Il-6* mRNA which was more highly expressed in the brains of PLX5622-treated mice compared to the brains of control mice in response to LPS (PLX x LPS interaction p<0.05), and *Il-10* mRNA which no longer trended to increase in

response to LPS in the brains of PLX5622 mice (PLX x LPS interaction $p < 0.05$, Fig. 1C). In the liver, PLX5622 attenuated the *Tnf*, *Il-10* and *Oas1a* response to LPS (PLX x LPS interaction $p < 0.05-0.01$) but had no significant effect on the response of other cytokines to LPS (Fig. 1D).

1.2 PLX5622 does not block the sickness-inducing effects of LPS

Statistics on the effects of PLX5622 and LPS on body weight and behavior are summarized in Table 4. LPS administration induced body weight loss (Fig 2A, 24 h vs. baseline, LPS x time $p < 0.001$) and this effect was not modified by PLX5622. LPS decreased locomotor activity in a new environment 3 h after treatment (Fig. 2B, LPS effect $p < 0.001$) and this effect was not modified by PLX. During the week preceding LPS treatment, mice fed the diet supplemented with PLX5622 ran on average 20% less than mice fed the control diet (PLX effect $p < 0.001$) and responded to LPS with a prolonged suppression of voluntary wheel running that lasted 3 days instead of only 1 day for the mice receiving the control diet (Fig. 2C, PLX5622 x LPS x time interaction $p < 0.001$).

2. Depletion of microglia by diphtheria toxin in knock-in rats does not attenuate LPS-induced neuroinflammation and sickness behavior

2.1 Administration of diphtheria toxin to *Cx3cr1-Dtr* rats eliminates microglia but does not abrogate LPS-induced neuroinflammation

The extent of microglia depletion was quantified by the expression of *Cx3cr1* mRNA in the rat hypothalamus. As expected, administration of diphtheria toxin abrogated the expression of this microglial marker in the hypothalamus (DT effect $p < 0.001$, Fig. 3A, Table 5). Peripheral macrophages were also depleted in the liver of rats injected with diphtheria toxin, as measured by the gene expression of *Cx3cr1* (DT effect $p < 0.01$ Fig. 3B, Table 5). Of note, microglia depletion was associated with an increased expression of the interferon-dependent gene *Oas1a* in the hypothalamus (DT effect $p < 0.05$) but not in the liver.

At 24 h after LPS, the cytokine response to LPS measured by *Il1b* and *Tnf* resolved in the hypothalamus of control rats but not in *Cx3cr1-Dtr* rats (DT x LPS interaction $p < 0.05$, Fig. 3A, Table 5). This indicates an exacerbated neuroinflammatory response to LPS or a delayed recovery). The same pattern was observed in the liver for *Il6* and *Tnf* (DT x LPS interaction $p < 0.05$, Fig. 3B, Table 5).

2.2 Administration of diphtheria toxin to *Cx3cr1-Dtr* rats does not block the sickness inducing effects of LPS

As described previously, administration of diphtheria toxin caused significant body weight loss by 48 h (DT effect $p < 0.001$, Fig. 4A, Table 6). LPS caused further weight loss 24 h after treatment (LPS effect $p < 0.001$, Fig. 4B) but the degree of loss did not differ between control and diphtheria toxin-treated rats. LPS reduced total locomotor activity in the open-field at 2 and 24 h after treatment only in those rats which had received diphtheria toxin (DT x LPS interaction $p < 0.05$, Fig. 4C, Table 6). There was a significant LPS treatment by time interaction for the number of center entries in the open field (LPS x time

interaction $p < 0.05$, Fig. 4D, Table 6), with an increase in center entries at 24 h compared to 2 h for the saline-treated group but not the LPS-treated group. However, there were no differences between the controls and diphtheria toxin-treated rats on this measure, which can be interpreted as indicating that microglia/monocyte ablation did not affect this form of anxiety-like behavior.

Discussion

The present results show that microglia/macrophage depletion either by PLX5622 in mice or by immunotoxin in transgenic rats failed to abrogate the peripheral and central inflammatory response to LPS. Therefore, it was not surprising that this treatment was unable to prevent the signs of sickness that developed in response to LPS. These unexpected findings indicate that the sickness inducing effects of systemic inflammation can occur independently from microglial activation.

As already reported in previous studies on CSF-1R antagonism(10, 11, 14), administration of the CSF-1R antagonist PLX5622 for 4 weeks resulted in the near complete elimination of microglia in the brain and a significant depletion of macrophages in the spleen and liver. An alternative to the use of CSF-1R antagonism to deplete microglia is the diphtheria toxin receptor-mediated cell knockout technique. This technique is widely used to remove specific cell types in rodents engineered to express the diphtheria toxin receptor on the surface of a specific cell type(17). Several variants of this technique have already been used to efficiently deplete microglia in mice(12, 18, 19) and in rats(15, 16) by coupling the diphtheria toxin receptor to the promoter of the gene coding for the microglia/monocyte specific marker CX3CR1. Diphtheria toxin itself is generally well tolerated when administered to wild type mice(20). In the absence of diphtheria toxin *Cx3cr1-Dtr* transgenic rats do not show any abnormalities(15, 16). Similar to mouse models utilizing conditional diphtheria toxin receptor expression approach (12, 33, 34), administration of diphtheria toxin in *Cx3cr1-Dtr* rats depleted microglia by 48 h in various brain regions including the hypothalamus, with repopulation occurring by 7 days(15, 16). Although microglia depletion was associated with anorexia and weight loss, this was not due to sickness as there was no change in locomotor activity in an open-field and in two tests of anxiety, the elevated plus maze and the light-dark box(15). There was also no indication of nausea as measured by ingestion of kaolin. In addition, microglia depletion by diphtheria toxin was not associated with any evidence of impairment in learning and memory as measured by short term memory in a novel object and place recognition tasks(16). Further studies indicate that the anorexia induced by administration of diphtheria toxin to *Cx3cr1-Dtr* rats is actually due to disruption of the gustatory circuitry at the level of the paraventricular nucleus of the hypothalamus(15), indicating the complex role microglia play in brain functions additional to their traditional role in regulating neuroinflammation(21).

We anticipated that the elimination of microglia by PLX5622 in mice and by diphtheria toxin in *Cx3cr1-Dtr* rats would attenuate neuroinflammation induced by LPS and its behavioral consequences. In accordance with this prediction, there are already several publications showing that depletion of microglia by PLX5622 protects from neuroinflammation(22-25) and prevents behavioral alterations in response to cranial irradiation(25), repeated social defeat(26), partial sciatic nerve ligation(27) and experimental

autoimmune encephalomyelitis(24). In addition, antibody-mediated neutralization of peripheral macrophage CSF-1R was reported to block the development of sickness behavior measured by reduced locomotor activity and body weight loss in response to CD40 activation, a model of autoimmune disease(28).

It is currently unclear why the elimination of microglia/macrophages by CSF-1R antagonism or by diphtheria toxin in the *Cx3cr1-Dtr* rat model failed to abrogate the inflammatory and behavioral response to LPS. At the periphery this could be due to the fact that both interventions specifically depleted tissue macrophages but did not affect pro-inflammatory monocytes recruited from the bone marrow, dendritic cells, or neutrophils which can all contribute to the peripheral inflammatory response(29). However, this cannot explain why the brain response to LPS was not only not fully abrogated in both models of microglia depletion but actually enhanced in *Cx3cr1-Dtr* rats. In the first study to show that CSF1 receptor antagonism eliminates microglia in a reversible way, mice were treated with a low dose of LPS (0.25 mg/kg) after only 7 days of the CSF-1R antagonist PLX3397, and brains were collected 6 h after LPS without intracardiac perfusion to eliminate residual blood (11). While this study showed that PLX3397 attenuated IL-1b and reversed TNF mRNA expression in response to LPS, it had only limited effects on other inflammatory markers, with no effect on IL-6 mRNA expression in response to LPS. In addition, a number of studies show that microglial depletion is not always neuroprotective. In mice infected with prions, administration of PLX5622 accelerated disease progression(30). In the same manner, PLX5622 increased viral load and enhanced mortality in a number of murine models of viral infection(31-33). A similar protective role of microglia was also apparent in the progression of neurodegeneration in APP-PS1 transgenic mice(34), the extent of excitotoxic injury in a model of brain injury induced by cerebral ischemia(35) and the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (36).

One possibility for the conserved production of cytokines despite microglia depletion is the well-known existence of genetically defined subsets of microglia in the brain(37-39) with differential sensitivity to genetic or pharmacological depletion. The techniques used to induce microglia depletion leave intact a very small percentage of microglia in the brain, less than 1% in response to CSF-1R antagonism(40). This resistant subset of microglia has been identified as having distinct self-renewal capacity following depletion and repopulation(40). However, its ability to produce cytokines in response to neuroinflammation has not been examined, and it is difficult to imagine that it is sufficient to induce a similar and even higher inflammatory response to LPS than the whole brain microglia population.

Another possibility is the compensation of microglia functions by other brain cell types. In the study on MPTP(36), flow cytometry analysis of chemokines and proinflammatory cytokines in astrocytes from the substantia nigra and striatum revealed that PLX5622 significantly increased the IL-6 and TNF response to MPTP. These findings can be interpreted to suggest that microglia cells down regulate the astrocytic response to inflammatory insults. There is already evidence that astrocytes from mice treated chronically with the CSF-1R antagonist PLX3397 to deplete microglia still respond to LPS *in vivo* by developing a reactive A1 phenotype(41). This is probably facilitated by the lack of IL-10 from microglial origin as this

anti-inflammatory cytokine normally lowers the proinflammatory profile of LPS- activated astrocytes(42). Activation of an astrocyte-dependent type 1 interferon response was also proposed to account for the gray matter neurodegeneration that was observed at a late stage in a model of diphtheria toxin-induced induced microglia depletion in a *Cx3cr1-CreER* mouse system(43). The possibility that reactive A1 astrocytes induced by LPS take over in the absence of microglia is consistent with the observation that in our study brain IL-6, a cytokine mainly produced by astrocytes during neuroinflammation(44), was the only cytokine of which the gene expression in response to LPS was enhanced by PLX5622. The increased expression of the interferon-dependent gene *Oas1a* in the hypothalamus of diphtheria toxin treated transgenic rats follows the same direction of change.

Another mechanism for the lack of attenuation of neuroinflammation by microglia depletion could be an enhanced trafficking of immune cells into the brain of microglia depleted mice. However, this is unlikely to account for the present results as it has been shown that PLX3397 treatment does not compromise the integrity of the blood-brain barrier, based on blue Evans coloration exclusion(11). In addition, in situations in which there was evidence of increased infiltration of lymphocytes in the brain of microglia-depleted mice, genetic elimination of lymphocytes did not modify the increased sensitivity of microglia depleted mice to neurodegeneration(36). The possible existence of a compromised blood-brain barrier has not yet been examined in the diphtheria toxin-induced transgenic model.

There has been no previous attempt to assess the effect of microglial depletion on the ability of rodents to engage in strenuous exercise, as measured by voluntary wheel running activity or by treadmill running. Our results show that PLX5622 decreased the amount of voluntary wheel running at baseline by about 20%. It is possible to interpret this finding in the context of what is already known concerning the involvement of microglia in the beneficial effects of physical exercise. In particular, microglial activation within the neurogenic niche has been shown to mediate the beneficial effects of running wheel activity on hippocampal neurogenesis in the adult or aged mouse brain(45, 46). In addition, wheel running has been reported to induce microglia proliferation in the adult murine cortex, which could play a role in the positive effects of physical exercise on neurological health(47, 48). Our observation of a significant decrease in voluntary wheel running activity in microglia depleted mice is consistent with this hypothesis.

A limitation of the current study is the absence of investigation of possible sex differences. We were unable to assess possible sex differences in the extent of microglia depletion induced by CSF-1R antagonism in mice or by immunotoxin in transgenic rats and in the effects of microglia depletion on the inflammatory and behavioral response to LPS as all the experiments were carried out in males. However, experiments carried out with PLX5622 and PLX3397 revealed no sex differences in the extent of microglia depletion induced by either of these treatments(30, 34, 49-52). In the same manner, female and male *Cx3cr1-Dtr* rats were found to respond identically to diphtheria toxin administration in terms of microglia depletion and body weight loss(15). This does not eliminate the possibility of an interaction between microglial depletion and the effect of the intervention, LPS in this case, as such an interaction has been described for the effects of microglial depletion by PLX3397 in rats fed a high fat diet. Microglia depletion

protected only male but not female mice from the deleterious effects of a high fat diet on executive function(53).

Conclusion

In conclusion, the results of the present study carried out in two different models of microglia elimination and two different animal species cast doubt on an exclusive role of microglia activation in the sickness inducing effects of systemic inflammation.

Declarations

Ethical approval: All protocols were approved by the University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee or RMIT University Institutional Animal Care and Use Committee

Consent to Participate: Not applicable

Consent for publication: Not applicable

Availability of data and materials: The datasets collected and analyzed during the current study are available from the corresponding author on reasonable request.

Competing Interests: RD has received honoraria from Pfizer USA and from Danone Nutricia Research France for work that is not related to the present study. All remaining authors declare no competing interests.

Funding: Funded by a Brain and Behavior Distinguished Research Award to RD, grants from the National Institutes of Health (R01 CA193522 and R01 NS073939) to RD, an MD Anderson Cancer Support Grant (P30 CA016672), a National Health and Medical Research Council Career Development Fellowship II (APP1128646), an RMIT University Ph.D Scholarship and an RMIT University Vice Chancellor's Postdoctoral Fellowship.

Authors' Contributions:

EGV: conception, design of the work; acquisition, analysis, **and** interpretation of data; drafting of the work and revised it.

SM: conception, design of the work; acquisition, analysis, interpretation of data; manuscript revision.

LS: conception, acquisition, analysis, interpretation of data; manuscript revision.

FGB: acquisition and analysis of data

SJS: conception, design of the work; interpretation of data; manuscript revision.

RD: conception, design of the work; drafting of the work and revised it

All authors have approved the submitted version and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Acknowledgements: We thank Plexxikon Inc. for the supply of PLX5622.

Author's information: Not applicable

Abbreviations

Cd11b: Cluster of differentiation 11b

CSF-1: Colony stimulating factor 1

CSF-1R: Colony stimulating factor 1 receptor

CX3CR1: CX3C chemokine receptor 1

Dtr: Diphtheria toxin receptor

E.Z.N.A.: Registered commercial name

IL-1b: Interleukin-1beta

IL-6 : Interleukin-6

IL-10 : Interleukin-10

LPS: Lipopolysaccharide

mRNA: Messenger ribonucleic acid

Oas1a: 2'-5'-oligoadenylate synthase 1A

PBS: Phosphate-buffered saline

PCR: Polymerase chain reaction

TNF: Tumor necrosis factor-alpha

WT: Wild type

References

1. Hart BL. Biological basis of the behavior of sick animals. *Neurosci Biobehav Rev.* 1988;12(2):123-37.
2. Vichaya EG, Laumet G, Christian DL, Grossberg AJ, Estrada DJ, Heijnen CJ, et al. Motivational changes that develop in a mouse model of inflammation-induced depression are independent of indoleamine 2,3 dioxygenase. *Neuropsychopharmacology.* 2019;44(2):364-71.
3. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci.* 2008;9(1):46-56.
4. Quan N, Banks WA. Brain-immune communication pathways. *Brain Behav Immun.* 2007;21(6):727-35.
5. D'Mello C, Swain MG. Immune-to-Brain Communication Pathways in Inflammation-Associated Sickness and Depression. *Curr Top Behav Neurosci.* 2017;31:73-94.
6. Ramirez K, Fornaguera-Trias J, Sheridan JF. Stress-Induced Microglia Activation and Monocyte Trafficking to the Brain Underlie the Development of Anxiety and Depression. *Curr Top Behav Neurosci.* 2017;31:155-72.
7. Dantzer R. Cytokine, sickness behavior, and depression. *Neurol Clin.* 2006;24(3):441-60.
8. O'Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. *Mol Psychiatry.* 2009;14(5):511-22.
9. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. *J Neuroinflammation.* 2008;5:15.
10. Han J, Harris RA, Zhang XM. An updated assessment of microglia depletion: current concepts and future directions. *Mol Brain.* 2017;10(1):25.
11. Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. *Neuron.* 2014;82(2):380-97.
12. Bruttger J, Karram K, Wortge S, Regen T, Marini F, Hoppmann N, et al. Genetic Cell Ablation Reveals Clusters of Local Self-Renewing Microglia in the Mammalian Central Nervous System. *Immunity.* 2015;43(1):92-106.
13. Acharya MM, Green KN, Allen BD, Najafi AR, Syage A, Minasyan H, et al. Elimination of microglia improves cognitive function following cranial irradiation. *Sci Rep.* 2016;6:31545.
14. Weber MD, McKim DB, Niraula A, Witcher KG, Yin W, Sobol CG, et al. The Influence of Microglial Elimination and Repopulation on Stress Sensitization Induced by Repeated Social Defeat. *Biol Psychiatry.* 2019;85(8):667-78.
15. De Luca SN, Sominsky L, Soch A, Wang H, Ziko I, Rank MM, et al. Conditional microglial depletion in rats leads to reversible anorexia and weight loss by disrupting gustatory circuitry. *Brain Behav Immun.* 2019;77:77-91.
16. De Luca SN, Soch A, Sominsky L, Nguyen TX, Bosakhar A, Spencer SJ. Glial remodeling enhances short-term memory performance in Wistar rats. *J Neuroinflammation.* 2020;17(1):52.

17. Saito M, Iwawaki T, Taya C, Yonekawa H, Noda M, Inui Y, et al. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. *Nat Biotechnol.* 2001;19(8):746-50.
18. Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, 3rd, Lafaille JJ, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cell.* 2013;155(7):1596-609.
19. Kitic M, See P, Bruttger J, Ginhoux F, Waisman A. Novel Microglia Depletion Systems: A Genetic Approach Utilizing Conditional Diphtheria Toxin Receptor Expression and a Pharmacological Model Based on the Blocking of Macrophage Colony-Stimulating Factor 1 Receptor. *Methods Mol Biol.* 2019;2034:217-30.
20. Chapman TJ, Georas SN. Adjuvant effect of diphtheria toxin after mucosal administration in both wild type and diphtheria toxin receptor engineered mouse strains. *J Immunol Methods.* 2013;400-401:122-6.
21. De Luca SN, Miller AA, Sominsky L, Spencer SJ. Microglial regulation of satiety and cognition. *Journal of Neuroendocrinology.* 2020.
22. Walter TJ, Crews FT. Microglial depletion alters the brain neuroimmune response to acute binge ethanol withdrawal. *J Neuroinflammation.* 2017;14(1):86.
23. Witcher KG, Bray CE, Dziabis JE, McKim DB, Benner BN, Rowe RK, et al. Traumatic brain injury-induced neuronal damage in the somatosensory cortex causes formation of rod-shaped microglia that promote astrogliosis and persistent neuroinflammation. *Glia.* 2018;66(12):2719-36.
24. Nissen JC, Thompson KK, West BL, Tsirka SE. Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery. *Exp Neurol.* 2018;307:24-36.
25. Feng X, Jopson TD, Paladini MS, Liu S, West BL, Gupta N, et al. Colony-stimulating factor 1 receptor blockade prevents fractionated whole-brain irradiation-induced memory deficits. *J Neuroinflammation.* 2016;13(1):215.
26. Lehmann ML, Weigel TK, Poffenberger CN, Herkenham M. The Behavioral Sequelae of Social Defeat Require Microglia and Are Driven by Oxidative Stress in Mice. *J Neurosci.* 2019;39(28):5594-605.
27. Lee S, Shi XQ, Fan A, West B, Zhang J. Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain. *Mol Pain.* 2018;14:1744806918764979.
28. Muller AF, Strauss L, Greter M, Gast H, Recher M, Becher B, et al. Neutralization of colony-stimulating factor 1 receptor prevents sickness behavior syndrome by reprogramming inflammatory monocytes to produce IL-10. *Brain Behav Immun.* 2015;48:78-85.
29. Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. *Blood.* 2012;119(8):1810-20.
30. Carroll JA, Race B, Williams K, Striebel J, Chesebro B. Microglia Are Critical in Host Defense against Prion Disease. *J Virol.* 2018;92(15).
31. Seitz S, Clarke P, Tyler KL. Pharmacologic Depletion of Microglia Increases Viral Load in the Brain and Enhances Mortality in Murine Models of Flavivirus-Induced Encephalitis. *J Virol.* 2018;92(16).

32. Sanchez JMS, DePaula-Silva AB, Doty DJ, Truong A, Libbey JE, Fujinami RS. Microglial cell depletion is fatal with low level picornavirus infection of the central nervous system. *J Neurovirol.* 2019;25(3):415-21.
33. Walzl I, Kaufer C, Gerhauser I, Chhatbar C, Ghita L, Kalinke U, et al. Microglia have a protective role in viral encephalitis-induced seizure development and hippocampal damage. *Brain Behav Immun.* 2018;74:186-204.
34. Unger MS, Schernthaner P, Marschallinger J, Mrowetz H, Aigner L. Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. *J Neuroinflammation.* 2018;15(1):274.
35. Szalay G, Martinecz B, Lenart N, Kornyei Z, Orsolits B, Judak L, et al. Microglia protect against brain injury and their selective elimination dysregulates neuronal network activity after stroke. *Nat Commun.* 2016;7:11499.
36. Yang X, Ren H, Wood K, Li M, Qiu S, Shi FD, et al. Depletion of microglia augments the dopaminergic neurotoxicity of MPTP. *FASEB J.* 2018;32(6):3336-45.
37. Han J, Zhu K, Zhang XM, Harris RA. Enforced microglial depletion and repopulation as a promising strategy for the treatment of neurological disorders. *Glia.* 2019;67(2):217-31.
38. Lee J, Hamanaka G, Lo EH, Arai K. Heterogeneity of microglia and their differential roles in white matter pathology. *CNS Neurosci Ther.* 2019;25(12):1290-8.
39. Masuda T, Sankowski R, Staszewski O, Bottcher C, Amann L, Sagar, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. *Nature.* 2019;566(7744):388-92.
40. Huang Y, Xu Z, Xiong S, Sun F, Qin G, Hu G, et al. Repopulated microglia are solely derived from the proliferation of residual microglia after acute depletion. *Nat Neurosci.* 2018;21(4):530-40.
41. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. *Nature.* 2017;541(7638):481-7.
42. Norden DM, Fenn AM, Dugan A, Godbout JP. TGFbeta produced by IL-10 redirected astrocytes attenuates microglial activation. *Glia.* 2014;62(6):881-95.
43. Rubino SJ, Mayo L, Wimmer I, Siedler V, Brunner F, Hametner S, et al. Acute microglia ablation induces neurodegeneration in the somatosensory system. *Nat Commun.* 2018;9(1):4578.
44. Van Wagoner NJ, Benveniste EN. Interleukin-6 expression and regulation in astrocytes. *J Neuroimmunol.* 1999;100(1-2):124-39.
45. Villeda S, Wyss-Coray T. Microglia—a wrench in the running wheel? *Neuron.* 2008;59(4):527-9.
46. Vukovic J, Colditz MJ, Blackmore DG, Ruitenberg MJ, Bartlett PF. Microglia modulate hippocampal neural precursor activity in response to exercise and aging. *J Neurosci.* 2012;32(19):6435-43.
47. Ehninger D, Kempermann G. Regional effects of wheel running and environmental enrichment on cell genesis and microglia proliferation in the adult murine neocortex. *Cereb Cortex.* 2003;13(8):845-51.

48. Jensen S, Yong V. Microglial modulation as a mechanism behind the promotion of central nervous system well-being by physical exercise. *Clin Exp Immunol*. 2014;5:188-201.
49. Janova H, Arinrad S, Balmuth E, Mitjans M, Hertel J, Habes M, et al. Microglia ablation alleviates myelin-associated catatonic signs in mice. *J Clin Invest*. 2018;128(2):734-45.
50. Hilla AM, Diekmann H, Fischer D. Microglia Are Irrelevant for Neuronal Degeneration and Axon Regeneration after Acute Injury. *J Neurosci*. 2017;37(25):6113-24.
51. Rice RA, Spangenberg EE, Yamate-Morgan H, Lee RJ, Arora RP, Hernandez MX, et al. Elimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus. *J Neurosci*. 2015;35(27):9977-89.
52. Elmore MR, Lee RJ, West BL, Green KN. Characterizing newly repopulated microglia in the adult mouse: impacts on animal behavior, cell morphology, and neuroinflammation. *PLoS One*. 2015;10(4):e0122912.
53. Smith BL, Laaker CJ, Lloyd KR, Hiltz AR, Reyes TM. Adolescent microglia play a role in executive function in male mice exposed to perinatal high fat diet. *Brain Behav Immun*. 2020;84:80-9.

Tables

Table 1 – List of mouse primers

Gene	Accession #	Foreword Sequence	Reverse Sequence
<i>Gapdh</i>	NM_008084	5'-GTGGAGTCATACTGGAACATGTAG-3'	5'-AATGGTGAAGGTCGGTGTG-3'
<i>Csf1r</i>	NM_001037859	5'-TGTATGTCTGTCATGTCTCTGC-3'	5'-AGGTGTAGCTATTGCCTTCG-3'
<i>Cx3cr1</i>	NM_009987	5'-TCCCTTCCCATCTGCTCA-3'	5'-CACAATGTCGCCCAAATACAG-3'
<i>Itgam</i>	NM_001082960	5'-CCACAGTTCACACTTCTTTCAG-3'	5'-TGTCCAGATTGAAGCCATGA-3'
<i>Il1b</i>	NM_008361	5'-GACCTGTTCTTTGAAGTTGACG-3'	5'-CTCTTGTTGATGTGCTGCTG-3'
<i>Tnf</i>	NM_013693	5'-AGACCCTCACACTCAGATCA-3'	5'-TCTTTGAGATCCATGCCGTTG-3'
<i>Il6</i>	NM_031168	5'-CAAGTGCATCATCGTTGTTCA-3'	5'-GATACCACTCCCAACAGACC-3'
<i>Il10</i>	NM_010548	5'-GTCATCGATTTCTCCCCTGTG-3'	5'-ATGGCCTTGTAGACACCTTG-3'
<i>Oas1a</i>	NM_145211	5'-GATGAGGATGGCATAGATTCTGG-3'	5'-AGGAGGTGGAGTTTGTATGTG-3'

Table 2 – List of rat primers

Gene	Accession #	Taqman Assay ID	Product Size
<i>Gapdh</i>	NM_017008.3	4352338E	63
<i>Actb</i>	NM_031144.2	4352340E	91
<i>Cx3cr1</i>	NM_133534.1	Rn02134446_s1	124
<i>IL1b</i>	NM_031512.2	Rn00580432_m1	121
<i>Tnf</i>	NM_012675.3	Rn01525859_g1	92
<i>Il6</i>	NM_012589.2	Rn01410330_m1	87
<i>Il10</i>	NM_012854.2	Rn01483988_g1	105
<i>Oas1a</i>	NM_138913.1	Rn04219673_m1	86

Table 3 – Effects of PLX and LPS on gene expression of markers of microglia/macrophages and proinflammatory cytokines. F values (F(1,20)) from 2 (PLX diet vs. control diet) x 2 (LPS vs. control) ANOVA with 6 mice/group. NS = non-significant, + p<0.10, * p<0.05, ** p<0.01, ***p<0.001

Target molecule	PLX	LPS	PLX x LPS
Brain <i>Cx3cr1</i>	F(1,20)=684***	F(1,20)=5.29*	F(1,20)=6.53*
Brain <i>Itgam</i>	F(1,20)=333***	F(1,20)= 9.61**	F(1,20)=7.56*
Brain <i>Il1b</i>	F(1,20)=1.43 NS	F(1,20)= 9.70**	F(1,20)=1.22 NS
Brain <i>Tnf</i>	F(1,20)=0.75 NS	F(1,20)=21.1***	F(1,20)=0.95 NS
Brain <i>Il6</i>	F(1,20)=0.30 NS	F(1,20)=7.56*	F(1,20)=4.55*
Brain <i>Il10</i>	F(1,20)=1.10 NS	F(1,20)=3.79+	F(1,20)=4.88*
Brain <i>Oas1a</i>	F(1,20)=0.29 NS	F(1,20)=14.7***	F(1,20)=0.31 NS
Liver <i>Csf1r</i>	F(1,20)=23.9***	F(1,20)=12.3**	F(1,20)=4.95*
Liver <i>Itgam</i>	F(1,20)=3.22 NS	F(1,20)=17.3***	F(1,20)=2.42 NS
Liver <i>Il1b</i>	F(1,20)=0.41	F(1,20)=27.1***	F(1,20)=0.34
Liver <i>Tnf</i>	F(1,20)=7.96**	F(1,20)=39.1***	F(1,20)=7.86*
Liver <i>Il6</i>	F(1,20)=2.49 NS	F(1,20)=23.6***	F(1,20)=2.44 NS
Liver <i>Il10</i>	F(1,20)=9.62**	F(1,20)=15.2***	F(1,20)=9.18**
Liver <i>Oas1a</i>	F(1,20)=4.15 NS	F(1,20)=28.9***	F(1,20)=4.53*

Table 4 - Effects of PLX on body weight, locomotor activity in a new cage and voluntary wheel running response to LPS. F values from 2 (PLX diet vs. control diet) x time ANOVA for body weight and voluntary wheel running before LPS treatment, from 2 (PLX diet vs. control diet) x 2 (LPS vs. control) ANOVA for locomotor activity in a new cage, and from 2 (PLX diet vs. control diet) x 2 (LPS vs. control) ANOVA with 6 mice/group with time as a repeated factor for body weight loss, and voluntary wheel running. NS non-significant, * $p<0.05$, ** $p<0.01$, *** $p<0.001$

	PLX	LPS	PLX x LPS	Time	PLX x time	LPS x time	PLX x LPS x time
Body weight	F(1,22)= 0.200 NS			F(6,132)= 3.85**	F(6,132)= 1.86 NS		
LPS effect on body weight	F(1,20)= 0.342 NS	F(1,20)= 1.14 NS	F(1,20)= 1.31 NS	F(2,40)= 65.2***	F(2,40)= 1.57 NS	F(2,40)= 31.0***	F(2,40)= 1.57 NS
LPS effect on activity new cage	F(1,20)= 0.186 NS	F(1,20)= 16.8***	F(1,20)= 1.36 NS				
Pre-LPS wheel running	F(1,22)= 18.4***			F(6,132)= 44.3***	F(6,132)= 0.803 NS		
LPS effect on wheel running	F(1,20)= 275***	F(1,20)= 7.45*	F(1,20)= 1.67 NS		F(5,100)= 4.24**	F(5,100)= 25.8***	F(5,100)= 7.90***

Table 5 - Effects of microglial depletion by diphtheria toxin on the effects of LPS on gene expression of markers of microglia/monocytes and proinflammatory cytokines in the brain (hypothalamus) and liver of *Cx3cr1-Dtr* rats. F values from 2 (diphtheria toxin (DT) vs. control) x 2 (LPS vs. control) ANOVA with 4-8 rats/group. Liver expression of IL-6 was undetectable in saline-treated wild-type and *Cx3cr1-Dtr* rats. LPS-treated groups were therefore compared by a Student's unpaired t-test. NS = non-significant, + $p<0.10$, * $p<0.05$, ** $p<0.01$, *** $p<0.001$

Target molecule	DT	LPS	DT x LPS
Brain <i>Cx3cr1</i>	F(1,23)=124***	F(1, 23)=1.14 NS	F(1,23)=0.16 NS
Brain <i>Il1b</i>	F(1,22)=4.05 NS	F(1, 22)=5.63*	F(1, 22)=5.47*
Brain <i>Tnf</i>	F(1,24)=13.8**	F(1,24)=2.78 NS	F(1,24)=6.17*
Brain <i>Il6</i>	F(1,24)=0.46 NS	F(1,24)=10.64**	F(1,24)=2.10 NS
Brain <i>Il10</i>	F(1,22)=1.55 NS	F(1,22)=8.40**	F(1,22)=2.27 NS
Brain <i>Oas1a</i>	F(1,22)=4.31*	F(1,22)=1.20 NS	F(1,22)=0.4 NS
Liver <i>Cx3cr1</i>	F(1,13)=14.2**	F(1,13)=8.42*	F(1,13)=4.58+
Liver <i>Il1b</i>	F(1,13)=7.45*	F(1,13)=7.78*	F(1,13)=0.79 NS
Liver <i>Tnf</i>	F(1,13)=9.35**	F(1,13)=36.4***	F(1,13)=11.7**
Liver <i>Il6</i>			t(6)=3.19*
Liver <i>Il10</i>	F(1,13)=0.82 NS	F(1,13)=1.02 NS	F(1,13)=1.12 NS
Liver <i>Oas1a</i>	F(1,13)=1.15 NS	F(1,13)=0.92 NS	F(1,13)=2.43 NS

Table 6 - Effects of microglial depletion by diphtheria toxin in *Cx3cr1-Dtr* rats on the effects of LPS on body weight and activity and center entries in the open field test. Body weight differences post-DT are assessed by a Student's t-test, comparing all wt with all *Cx3cr1-Dtr* rats (16-17 rats per group). F values from 2 (diphtheria toxin vs. control) x 2 (LPS vs. control) and time as the repeated measures ANOVA with 7-9 rats/group. NS = non-significant, * p<0.05, ** p<0.01, ***p<0.001

	DT	LPS	DT x LPS	Time	DT x time	LPS x time	DT x LPS x time
Body weight	$t(31)=16.6^{***}$						
LPS effect on body weight	$F(1,28)=0.03$ NS	$F(1,28)=24.3^{***}$	$F(1,28)=0.12$ NS				
LPS effect on activity in the open field	$F(1,28)=20.7^{***}$	$F(1,28)=21.6^{***}$	$F(1,28)=5.21^*$	$F(1,28)=0.01$ NS	$F(1,28)=1.19$ NS	$F(1,28)=1.84$ NS	$F(1,28)=1.44$ NS
LPS effect on center entries in the open field	$F(1,26)=3.55$ NS	$F(1,26)=12.2^{**}$	$F(1,26)=0.08$ NS	$F(1,26)=8.80^{**}$	$F(1,26)=0.01$ NS	$F(1,26)=4.68^*$	$F(1,26)=0.24$ NS

Figures

A. Brain

B. Liver

Figure 1

Figure 1

Effects of microglia depletion induced by PLX5622 on the neuroinflammatory response to LPS in the brain and liver. CTL = control diet, PLX = diet supplemented with PLX5622. Mean $\pm$ SEM, $n=6/\text{group}$, * $p<0.05$, ** $p<0.01$, *** $p<0.001$ (post hoc statistics when significant interaction)

Figure 2

Figure 2

Effects of microglia depletion induced by PLX5622 on the effects of LPS on body weight expressed as percent change from the baseline, locomotor activity in a new environment measured as distance traveled (cm) and wheel running activity measured by total number of rotations per night at baseline and during 5 days after LPS administration. CTL = control diet, PLX = diet supplemented with PLX5622. Mean $\pm$ SEM, $n=6/\text{group}$, * $p<0.05$, ** $p<0.01$, *** $p<0.001$.

A. Hypothalamus

B. Liver

Figure 3

Figure 3

Effects of microglia depletion induced by administration of diphtheria toxin to Cx3cr1-Dtr transgenic rats on the neuroinflammatory response to LPS in the hypothalamus and liver. Mean $\pm$ SEM, $n=4-8$ /group, * $p<0.05$, ** $p<0.01$, *** $p<0.001$.

Figure 4

Figure 4

Effects of diphtheria toxin on (A) body weight measured 48 h after in Cx3cr1-DTr transgenic rats compared to wild type (WT) rats, (B) on LPS-induced body weight changes measured 24 h post-LPS, and (C) on locomotor activity measured by distance traveled and center entries in an open-field test carried out 2 h and 24 h post-LPS. Means +/- SEM, n=8/group except for (A), **p<0.01, ***p<0.001